N
Google TrendMONTEZ SWEAT (1000+) — Bears DE Montez Sweat suspended 2 days for drug violation
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:montez sweat1000+rob lowe1000+tanner hudson500+frozen frenzy200+payton pritchard1000+huevo500+winter weather advisory2000+joão cancelo1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Cutaneous T cell lymphoma" (30 stories)

Top Headline Story

Consensus Helps Dermatologists Spot CTCL Mimicking Atopic Dermatitis on Dupilumab
Lead StoryThe American Journal of Managed Caregeneral
1d ago

Consensus Helps Dermatologists Spot CTCL Mimicking Atopic Dermatitis on Dupilumab

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxONzhWdlVCXzRqSWF5RFJUM1VQeVlDOThrTFpUT21KendhNjlDQnA5WFlnWjdMOHBwRmNScEJOdGVyU3BzdWsyTzRYMjVUWHkyX252Vm1FN19aWWJzQlVUekNwMjNxWDlrUVpnS1pEaE13UHlnQlpMM296bFYxZEhnMVpZS1lQZXQyZUp5czQ4eGlCNWM5RkdmdlU0TQ?oc=5" target="_blank">Consensus Helps Dermatologists Spot CTCL Mimicking Atopic Dermatitis on Dupilumab</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+24m ago

montez sweat

Bears DE Montez Sweat suspended 2 days for drug violation

Filter stories
1000+34m ago

rob lowe

Daily Wire's 'Confession': Details Revealed For James Franco, Rob Lowe Film

Filter stories
500+34m ago

tanner hudson

Bengals tight end Tanner Hudson out for season with torn pec

Filter stories
200+34m ago

frozen frenzy

The top reason to watch every NHL team in the Frozen Frenzy

Filter stories

Search Results for "Cutaneous T cell lymphoma"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome
BioSpaceworld

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxNUzlPN29LY0xWZEN5SWQ3TkdQdTlURm5HSXRsQ3JnMnhMVUs0QkZWRzRzQWNBMmU4Wlp6TDdDRHRyNzJKRVhOQUZTMlpkaUQtMUJTeWJBaVFYeVBWRVh1R20tejE3RlNLck5IZGp1bkJkYjgyZFZBOEtqWnJSWndXN0VaM3RLMFRnbnVhQ3N1ZzlTcFFWVDg2c2MyM1JNSzBrRzBfT0JzMU04aVR5dTdRUE9FUmZUR1lqQV9mSEprWE9kMnJoeEE0UlUtWmVhQVZDRlNNRlJZWDh2bUdPSlNTUHpyR2M0b1o4cFBSTjFWN1NyYXVubmR1MktJbGQ3aEE4NERlOGNwNDRPdw?oc=5" target="_blank">Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Dupixent Lawsuit for T-Cell Lymphoma
Lawsuit Information Centergeneral

Dupixent Lawsuit for T-Cell Lymphoma

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPd045TzFIcDJtMXEwOW1pcTVkUGx6Y3Y3Q1pYVmlDV18wY3JxUFZ0SjZFdV9aQ01nVXdzbWJ3SExjLVcwb0xNdnhCcFJSYTdUX1lEemlldUw0a2dJSWpkaHQwZ3VXdVF5SkxYVmcyYUQyeGZlR2RLOHhBSnI0RTZnOHNZWWR6dTA?oc=5" target="_blank">Dupixent Lawsuit for T-Cell Lymphoma</a>  <font color="#6f6f6f">Lawsuit Information Center</font>

Read Full StoryMore like this
ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma
OncLivegeneral

ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTWNSZk5OUlVfOW5uUkFoNHRrQmJsaENfeXMzU2l2TXVwRjZyck5lVm5DeVdoMzY2ZGFvM1BkUjh3T1BZMzRPWnV5akZCMmQtX0kxQ2o4clV3RlFRQ1FIUjVKRmJ2bG1keGhQd0hBTXNRTGxrSFc5QkEtNkVQN0hidWlYQm85U2ZKZ05xVmt5ZDJpM1FnWHlSVWdqcEV1SEc3cWZUVTFKNVI2LVBpcVJmWDA4S0tpMWdwMUFyeXNTUVRnZw?oc=5" target="_blank">ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Beyond the Rash: Cutaneous Peripheral T-Cell Lymphoma as a Diagnostic Pitfall in Primary Care
Cureusgeneral

Beyond the Rash: Cutaneous Peripheral T-Cell Lymphoma as a Diagnostic Pitfall in Primary Care

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOdmNOMUY0a1F6ekZwanF5VXNrUlNLaHp2WEtQbkRPbENtZjFIbUxMaDJLblljRW14d20xYlVPZ2p6ZFJvUWxod09CbEI0MENKTnZuZHdBTFlMMUZKX2szX0RqOU5za0Rnb2ZvRjBqRDVweFRTRXRxRHc4MWVFVFY1S2JRYktVdEpOZ1RHNmxtT1FiREVpeGtuLVlhZDlGTW84UmwxX1Bqc09VcUtOREl3TGkzRnA0UXg3c19qQXNaV2EtT2Myc2NBRGpQZw?oc=5" target="_blank">Beyond the Rash: Cutaneous Peripheral T-Cell Lymphoma as a Diagnostic Pitfall in Primary Care</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Cutaneous T-Cell Lymphoma: When to Worry in MF/SS—and What’s Next in Targeted Therapy
HMP Global Learning Networkgeneral

Cutaneous T-Cell Lymphoma: When to Worry in MF/SS—and What’s Next in Targeted Therapy

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxON3lEMWtJTkVDaWxwWFVBNkVSeC1VWDdwYVdvVm9CeFQ3cDFieEYwSnlQa3Y5RDU0TGxCMHRBODl2emNQYVpHQkxjX0RGbDVXQ1hkRjd3dHBleVRseDFYVzY4QjQ5QTdQeXV2T1F4cWxadE9ob05FWXktVUFBVHJjM0g0cm8zY2tVTjB3aTJhVjBlLVlpekRPMVZXakxUM2l3bTEyaC1ZZ1dodlkySE9PeDlmczFYTWhEdVF5Nnp0UGUwSWFock1YY0hXajRBTGdBMnd4WVRn?oc=5" target="_blank">Cutaneous T-Cell Lymphoma: When to Worry in MF/SS—and What’s Next in Targeted Therapy</a>  <font color="#6f6f6f">HMP Global Learning Network</font>

Read Full StoryMore like this
T-cell lymphomas: From diagnosis to treatment and beyond
Penn Medicinegeneral

T-cell lymphomas: From diagnosis to treatment and beyond

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPb2hPN2lUWGlKTGRqaV8yWnp1Q1JmclJGb3NDblNLVjRYQTExLVE2NFZoNlM0QVpvVE9rYThVcFhHdy1Ba0FzYzRFWXU5UnAyYURRVmNDTnBHSDlQbVdxTnJsUDlDcmo5bVVtamM1dXl1aW80VHYyNzlFUURxMTE5MUdiOE9lQ1NPaG03YTZiOTF1SmRSZEFEVlREUDFmOHJIektkZ01WV3o?oc=5" target="_blank">T-cell lymphomas: From diagnosis to treatment and beyond</a>  <font color="#6f6f6f">Penn Medicine</font>

Read Full StoryMore like this
Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas
Frontiersgeneral

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQcnZpUFRHS2dEcTVrSFljQkdLZnUxX0l6SjJSTk9EOHRvbkZhSjNDYlRzZDRRSW1PYzZlWFdpYzJBbC1kdk1kcFpRZWliZDFhblZFZkdKNjBOb1djalUyeTYwUy1acWR3Q2VsTFFFWkRPeWVkTzBqdGhzWEltQU5tTkJwbFdqMDk2dFpaNVlycktyQQ?oc=5" target="_blank">Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Journal of the European Academy of Dermatology and Venereology
Wiley Online Libraryworld

Journal of the European Academy of Dermatology and Venereology

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE53U1ZwM1ZUa0pFSlROb3RWUzgybXY4TFZKVW43OGJfcFNSMWJ4R0R0c3BxNzRHTk5uREhfY1ctM1pKc3lOeXRZZjFGYWxjQXFreHgzUXJfaFR2Q0tScGdCRENZRTBualVjSUE?oc=5" target="_blank">Journal of the European Academy of Dermatology and Venereology</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Dupixent Cutaneous T-Cell Lawsuits: Learn About Your Rights
ClassAction.orggeneral

Dupixent Cutaneous T-Cell Lawsuits: Learn About Your Rights

<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE1XMjc3bUhOdlFaWG9IWGw3RGZ0R0x2QTIzdGtrNVJTcWRKa214cXhxVkhFV3RMOVBHdC14N0lqc0d1a0NNUHg4V2psYTJiLWM0akg1b2RvT3dnb2hSR0JJNmtpcVI?oc=5" target="_blank">Dupixent Cutaneous T-Cell Lawsuits: Learn About Your Rights</a>  <font color="#6f6f6f">ClassAction.org</font>

Read Full StoryMore like this
Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression
Natureworld

Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE44dXlwZXRJeDJQeWNPbEp6Y0JHMVFzeFBXMno1cFlGYlJjN3otMlE3LUs0ZjNqRW1LNXVHeVJvVG5fWHpQRGRfRGYxQVNsQ1hSVXc3MGkwSUd0SHFfMU9z?oc=5" target="_blank">Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO
Business Wiregeneral

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO

<a href="https://news.google.com/rss/articles/CBMizgJBVV95cUxPNERJYjJoVEtNSFluLVI2b1JXVUEtM3NNemFsNDZaZnhFeW9CUUpoeFpqdlVvVGpXS1RmUWVxWEdxVDByQkpYZGxLbkRyendqUUl0SUh3aThDWXUxSnJ0czkxMjBfSnMxYWN1R29Ed1lscnNPeWpyWl91YUlILUFraWxaNmd6WU1ScFQxMVFBNlREdnhBSGRhNkJnMzBOaHIxYlpibGZrdGsydEsxTHEwUlZvbVRsam9fazRoT0MxVGwxSl9kNmxtdlJ3cXFRYTBqd2RxVktxZjNVUFk1N09qcTRXX0ZoS1JjUnBzcm4xeHdRaHBOTnhVQ0pWeDRDbTJtVUdiOG1WRXhpRDlpaFJJME9manB6NjhfQU1yVWIwVERXcjYyclhSYWdub0hHTl9WT0VVTjFmNTgxY2IwcHN2ZVFNbmlyRlpUN0J0YXNn?oc=5" target="_blank">Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Cutaneous T-cell lymphoma in adult atopic dermatitis patients treated with dupilumab or tralokinumab
Springer Nature Linkgeneral

Cutaneous T-cell lymphoma in adult atopic dermatitis patients treated with dupilumab or tralokinumab

<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5rSWJSSFlkeVJTZEhVenQzeGtlbmstcUY1Yl9WTW9VaThXc1RNT3h5d3dzZmF0UVpDZ21qS2pmTjFvSThEcXVJTE9YMm80c0pKQXY1bkNsMEdaWWJQTzVrb3FEWTlNNVUwT29uTg?oc=5" target="_blank">Cutaneous T-cell lymphoma in adult atopic dermatitis patients treated with dupilumab or tralokinumab</a>  <font color="#6f6f6f">Springer Nature Link</font>

Read Full StoryMore like this
Expert Insights: FDA Approval of Lymphir for Cutaneous T-Cell Lymphoma
Cure Todaygeneral

Expert Insights: FDA Approval of Lymphir for Cutaneous T-Cell Lymphoma

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPUUluREVHbDZJVFJSUERSR1g3X2lHazdNbFdqSTZyRmJ0bnBfMlB1RTdXMmotUGlxT2Q4ODVNZlB6MzBoMFZ5SGxPOWdvbjJtMGN1bURPNld4QzQweGhBWnBBMGluVnoxZGgyMTJDQWJWTWFZZDFwZ194R2NDS2lHVE1KS216eDJWOEhIS1V6SFBvQjhfLTM2VG5RblphTFZhbXc?oc=5" target="_blank">Expert Insights: FDA Approval of Lymphir for Cutaneous T-Cell Lymphoma</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
Point of Pure Return: Denileukin Diftitox-cxdl for Cutaneous T-Cell Lymphoma
Pharmacy Timesgeneral

Point of Pure Return: Denileukin Diftitox-cxdl for Cutaneous T-Cell Lymphoma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOVGR6bmRWS3hxMUNyS2RNSVhKWHY3TW5SRTc0Uk9jbVQxNDVTRFNFOElnMlNmb2pLWGRNV3BDdnNKZElyZzcwWjlobUhVckxld29iNTl5d0VkTlZYYmxlREppMFk2a2I3ZTdvd2xTVW1WRU1LT01DNEM3S0hmRURnNk9zc0FHTUc1UGlsTFJ0bXFTcTgtczJyN1ZPalUxS3FlQXhhUUR3ZF8yMzRCaGlz?oc=5" target="_blank">Point of Pure Return: Denileukin Diftitox-cxdl for Cutaneous T-Cell Lymphoma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Dupixent Lawsuit | T-Cell Lymphoma Cancer Side Effects - October 2026
AboutLawsuits.comgeneral

Dupixent Lawsuit | T-Cell Lymphoma Cancer Side Effects - October 2026

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5mZE5Bb29uNVF6a2tsRk0xQ01NcVhReXo3aHUxbndZYldkZ0dTVGtmTW95ckc4TWlrTV9ZRF8xVnFiQzl6TDBHVGljSFYzNUNfb0dPRVVpbmZkOU0?oc=5" target="_blank">Dupixent Lawsuit | T-Cell Lymphoma Cancer Side Effects - October 2026</a>  <font color="#6f6f6f">AboutLawsuits.com</font>

Read Full StoryMore like this
Moderate-Dose Local Radiotherapy in Symptomatic CD30-Positive, Anaplastic Lymphoma Kinase (ALK)-Negative Primary Cutaneous T-cell Lymphoma
The Cureus Journal of Medical Sciencegeneral

Moderate-Dose Local Radiotherapy in Symptomatic CD30-Positive, Anaplastic Lymphoma Kinase (ALK)-Negative Primary Cutaneous T-cell Lymphoma

<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxNZGdqZ1VjaDVLaDV6Q1VzZG9ORXJoTGtnV0o5UWdkQ2RoeGtyUlVqQ1NDNkpzWnZQSGk0Y2xXYTA5aVlUTVJSOEpjajdmVXA5UWtrN0F3aFNsazRQZFlaTENFUFdiS3B6MkhxeHFQVXhOT1dKdFB0VmdySVJQVDhsaTlGM2VQUlNrZTVEWGJPS3hRUDVYaGc4YzY2YlhxN3NFOGdDMUdONTVHenN6ajlDWDBDQ1FBRl9idjBsN2x6RFU1VFJTV3FseC1lUFFfQTlleTM5WS1xUGFIc0ducEJvS2Q1Yk5vQ0VnRWdHT2l5aFpJMGRoZHlUNURZQUhtbnhEa1JXbw?oc=5" target="_blank">Moderate-Dose Local Radiotherapy in Symptomatic CD30-Positive, Anaplastic Lymphoma Kinase (ALK)-Negative Primary Cutaneous T-cell Lymphoma</a>  <font color="#6f6f6f">The Cureus Journal of Medical Science</font>

Read Full StoryMore like this
BI-1808 Shows Efficacy as Monotherapy and in Combination With Pembrolizumab in T-Cell Lymphomas
OncLivegeneral

BI-1808 Shows Efficacy as Monotherapy and in Combination With Pembrolizumab in T-Cell Lymphomas

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPbHNzRmJCaENvcjdWNkJHeUpwTGh6VkFOSjJtUVdJVHhOUmRyZTA2X2JXcnZGZ014UU5UbzNZNzdUQkQtS1JqSXlvUmY2TmRSOXpDTjdkX21xbC1ZWTA5MmJ0ak5LZFJSU2NzTFkzcUhxMXZyUXprMmpfem0xWUYxQTd2M2t4MkZtV2dNbzNfWlFUOGJLREVGOGF0SWh1M3NnOW4zTU05MWhtdXd6N2xzQ3FNX0RUVEdSUnNtU0c0czd2UQ?oc=5" target="_blank">BI-1808 Shows Efficacy as Monotherapy and in Combination With Pembrolizumab in T-Cell Lymphomas</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Multidisciplinary Approaches and Managing Skin AEs are Crucial to CTCL Treatment
OncLivegeneral

Multidisciplinary Approaches and Managing Skin AEs are Crucial to CTCL Treatment

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOTEdHbnhFX0o4YlFLWk5QR1VPRjdrYzdyVUFsaThPbXAzNllMNUdDbEtoU0txYXZUVENoS1FCYl9aUTdjV2h3ZG1CZFhyZWhSd0FUb18yZHF0Ml9kN3I0aEhwYzlMZ1F1c2p5Q2x2UUd5WHJYQndYU3NPV01sd010ZHNRYmlSTGNwclpHRGlxS1dpVEd2TlBZSGpDb1Q0Y29yV2t0UU9nZjVpZFd5V1E?oc=5" target="_blank">Multidisciplinary Approaches and Managing Skin AEs are Crucial to CTCL Treatment</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
OncLivetech

MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQdXBnenlpbjdqYzRZbDBpNDV1VWwxd3c1dThYd0FwUkZUYlJGak1GUXdrd1RlRlZtemIydEdSTUs5RzRpcHNObi16WG1ybHlxMjRSdk5ERGNyT3p4ZkkxaHJNTWFiUGhqZ0RXUjVuQlhxM3FjQ1BEUWd4V09UNVNfYjdnSnFEYVhJRmJLREtRYjdlTjd0NkRTVFQzT2prd3RZRmFiSXNIVWlhSUtnME5fX2FNdnNUeWxMVXYyVS1R?oc=5" target="_blank">MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review
Frontiersgeneral

Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOaXctU1ZYMGtSc05sbldrWEM0WVhockZ1dlhma3BLNGZKdGZCUnB3MVZKTG1ab3dwM2FVSGV6a1VqTXd1cjRWejJVZ0RiVFZKSHpiOFJLWGJXNUY0cWJNaktEQWpsMzdTbUV3UGsyZmE1Q0tHTlNfcTJSUmpUQ1ljTTBaRHFYMVZWZWtIWmhB?oc=5" target="_blank">Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
NCCN Adds Duvelisib to Clinical Practice Guidelines for CTCL
Targeted Oncologygeneral

NCCN Adds Duvelisib to Clinical Practice Guidelines for CTCL

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEJzUHJnRmNLbmJhSFFadlNKM09lZ2ZydkwwSHhJVHNzZWtYNzVrMDV0NnNZdWI5VndRbTFWeVlTaGlEME5UYWNsZXQxaVlUN0NSVFpaZzFwTThzYnR5OFFaamVRR1VGZlI4WXI4c0xlRUg1Ukpvd0dfMU9RYlJzNFFOSk9LZ0twYWdpQ0ZVLWFLOGxKN3l6Yw?oc=5" target="_blank">NCCN Adds Duvelisib to Clinical Practice Guidelines for CTCL</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Denileukin Diftitox to Expand Across EU for R/R Cutaneous T-Cell Lymphoma
Targeted Oncologygeneral

Denileukin Diftitox to Expand Across EU for R/R Cutaneous T-Cell Lymphoma

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOS1paWWhCSmduOFVpcGx4aE5NQ2ltSmltNmp6bjdSTUFOVUN6UU1HS1hxTFlwWS1NcjdqM1VUTUFkd293bGxYM0d4QnZDWGZwdnhsWWtSc2pzVVBObE4tY1Z0b2RDRHRJX2tNZDhvRkMyZTA2aGhJNFd0MnhiTXdfdWc2RDducUJ0dkdVdlhIWHhTbUdTN0YzYXZzaFM2UFZhSzRkTzBVNVBnZw?oc=5" target="_blank">Denileukin Diftitox to Expand Across EU for R/R Cutaneous T-Cell Lymphoma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Dupixent and Cutaneous T-Cell Lymphoma: What Patients Should Know About the Growing Litigation
JDSuprageneral

Dupixent and Cutaneous T-Cell Lymphoma: What Patients Should Know About the Growing Litigation

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQRVJKd0VvN1RJOUhPZ1R6Q2tyRGY3MFpaR3ZNN0ZBOTl1THdZT3gtcXJuRVB3REJUY1IxR0tleUdCNDNuWTUwcWVQWjZxb0N2NHNYaVdZVEZvZXhmU0lZOTN6NXFXSjRkcUFidlVXMXQ4bmZWN3pWblloajBrSlppQS1ZbWQ3eDRU?oc=5" target="_blank">Dupixent and Cutaneous T-Cell Lymphoma: What Patients Should Know About the Growing Litigation</a>  <font color="#6f6f6f">JDSupra</font>

Read Full StoryMore like this
Soligenix axes lymphoma program after phase 3 setback, mulls M&A options
Fierce Biotechgeneral

Soligenix axes lymphoma program after phase 3 setback, mulls M&A options

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNUnNLQ3d1RHpidzJzcmZZc1dLUU5qdElzaXRMbXB3SWtRMm5QNW4zdGpoMW9uMDN0ZTZnTGF0T2ZudVhrdGNkc0VRSXBna1pIVXA0MHoxSVE5aXlPb3lzM2x0RjVMWmRMbjBtV1hEYXBOdnllVFY3Ync5dU0xaGpOaW1jQy0ta245NzdLOWJVT2l0am1KSm5nLW9ESUdtMXlvV2ppOWplNGNPd0VC?oc=5" target="_blank">Soligenix axes lymphoma program after phase 3 setback, mulls M&A options</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
10 Experts Predict the Future of CTCL Treatment
OncLivegeneral

10 Experts Predict the Future of CTCL Treatment

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE05WHc4VnE3cFZ1R3pmWkRRZ21ydW80RUxRMnE3WEZwYmh6LU1ocTl5ZzQyWjJncVpKa0ZYRXVLQkhNel80Vl81eElmdjdHLTdhWmJxOXg2TlpiQi1odVVCYndKaW80cU5KdmE0MHc0TXRhd2NQU0tZWg?oc=5" target="_blank">10 Experts Predict the Future of CTCL Treatment</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Duvelisib Plus Nivolumab Elicits Responses, but imAEs Limit Dosing in Pretreated CTCL
OncLivegeneral

Duvelisib Plus Nivolumab Elicits Responses, but imAEs Limit Dosing in Pretreated CTCL

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPOUlBUHJXRDNlUzh3SjdBNXBENm9wOFhEdjl6dWY0b0tfRnlkalVhalNHZ240c0Q5WW8xN25ySVpJd1NaNkNqekZLX1Z4OXptZHp5Q1lzQjdhRWhVSWpFYWlPb0dVYUNPRkxLSTc1cGNxdmhlVDhSWTZWeXA3N2V3Nm8tRjctYzl0cFMxckd2T0EtXzkxai1VbVpxWQ?oc=5" target="_blank">Duvelisib Plus Nivolumab Elicits Responses, but imAEs Limit Dosing in Pretreated CTCL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Mogamulizumab Improves Quality of Life in Real-World MF and SS Study
Oncology Nursing Newsworld

Mogamulizumab Improves Quality of Life in Real-World MF and SS Study

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNNkd6Z09kdzFDc0dtM2M1ZElDMFF6d0p6N0lDLUxBYTR1MHUySXFRSWJyaHk2NEc5cTUwQ29MM0xQWDYyaDVPX0FmN2hoMXUxQzctQ2RadHFuT2lseTY0NEtQVVlGcjJXUVVSUTJsaHFXRzFEMWhoUTlPVXIzb3NQSkJfT1pVS2lZc25HZjdHTmtLWUlISXZveWx3eWMzWE9WOEVnS2lpRQ?oc=5" target="_blank">Mogamulizumab Improves Quality of Life in Real-World MF and SS Study</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
Dr Mehta-Shah on the Future of CTCL Novel Drug Development
OncLivegeneral

Dr Mehta-Shah on the Future of CTCL Novel Drug Development

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxObUhaNld3SERVRm8xXzZpWGRDLUpuUVZaWnNhZkgtOVJTdkFLaDhTM2lfbXE1a2F0OWlKRXZaTjZzZjNWNFY5ajlDcDFvbFV2eVVhZVRrc2hsOUhnQ1dKemtWcE1mUEFMM21PWkRwcG9jZ2ZVX3lnMlNLN2FaazM4ZWNtQ013Yy1qaU1ZYlhJdmU?oc=5" target="_blank">Dr Mehta-Shah on the Future of CTCL Novel Drug Development</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Dr Mehta-Shah on Novel CTCL Target Research
OncLivegeneral

Dr Mehta-Shah on Novel CTCL Target Research

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTFB6bnRLVE5qb05DYkU4d1hpcnlYRW9VbENHblROZEY2aUgxaEF2Vk1ZN2lINW1vTUhYbUU0THp5X1V0UTZEZ0pUQ0k4LUZYTFNqTHFhRkMwaTVxSkQ3RER0elNpZW1WYVhJNElLS2pxaFZGTUdqNks1eU5Vd1c?oc=5" target="_blank">Dr Mehta-Shah on Novel CTCL Target Research</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
"Cutaneous T cell lymphoma" — Live Google News Trends & Headlines